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A B S T R A C T
Radio- and chemotherapy are the most common cancer treatment modalities. They cause acute and late side
eﬀects on normal tissues, which is a burden for delivery of a high dose of radiation or drugs on tumor cells. In
addition, tumor cells achieve adaptive responses to subsequent doses of radiation and chemotherapy, leading to
tumor resistance and accelerated repopulation. Resistance to radiotherapy and chemotherapy can occur fol-
lowing adaptive responses, which itself is due to the release of large numbers of inter- and intracellular med-
iators by immune cells as well as other tumor microenvironment (TME) cells. Melatonin is a potent natural
antioxidant and anti-inﬂammatory agent that protects against toxic side eﬀects of radiation and chemotherapy.
Furthermore, in some cancer cells, melatonin aids sensitizing cancer cells to therapy. Apoptosis is one of the
main mechanisms of cell death following exposure to radiation and chemotherapy. Evidences have shown a
direct relation between apoptosis induction in tumor cells with increased tumor delay regression and survival.
Melatonin through modulation of several apoptosis mediators such as mitochondria, Bax, Bcl-2, endogenous
ROS, and apoptosis receptors facilitate apoptosis. The current review aims to explain mechanisms of apoptosis
induction following exposure to radiation and chemotherapy drugs. We also reviewed the modulatory eﬀect of
melatonin on apoptosis signaling pathways.
1. Introduction
Cancer is one of the major health disorders worldwide. In 2018,
more than 1.7 million new cases of cancer were diagnosed in the United
States. Estimates have shown that cancer accounted for more than
600,000 deaths in 2018 in the United States [1]. Preventing cancer
incidence, control of cancer growth, or its complete eradication are
major aims for cancer-related researches. Radio- and chemotherapy are
the most non-surgical cancer treatment modalities. For treatment with
radiotherapy, patients receive a high total dose of radiation over weeks.
However, for chemotherapy, patients receive a type of drug based on
their cancer. This may take several months to complete the treatment
course. For most patients, chemotherapy may be followed by radiation
therapy aiming for more eﬃcient outcomes [2].
Besides the crucial role of radio- and chemotherapy for tumor
control, several experimental studies have conﬁrmed serious toxicities
of both modalities on various organs [3–5]. This issue is more obvious
for organs with high proliferation activity [6,7]. Exposure of cells with
high mitotic index to radiation or chemotherapy drugs lead to severe
DNA damage and cell death, especially through apoptosis [8,9]. If
normal tissues are exposed to a high dose of radiation or chemotherapy
drugs, high rate of apoptosis may lead to organ failure [10–12]. Bone
marrow and gastrointestinal (GI) system, which are the most critical
organs in response to radiation/chemotherapy contain high pro-
liferating and sensitive stem cells [13–16]. Tissues such as parotid
glands, ovary, testis, lens, spleen and skin also have proliferating cells
and may show severe reactions following exposure to high doses of
radiation and chemotherapy [17,18].
Apoptosis plays a key role in the response of tumor cells to radiation
and chemotherapy [19,20]. Tumor microenvironment (TME) via
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secretion of cytokines and chemokines modulates several signaling
pathways that are involved in the resistance of cancer cells to apoptosis
[21–23]. Regulatory T cells (Tregs) and macrophages are the main
immune cells within TME that inhibit apoptosis. Hypoxia plays a key
role in recruitment of these cells to TME [24]. These cells release sev-
eral mediators that exhaust lymphocytes, thus attenuate immune re-
sponses against cancer cells. Hypoxia also triggers autophagy, which
supply cancer cells fuel and inhibits apoptosis [24]. Overexpression of
anti-apoptosis genes such as NF-kB, PI3K, Bcl-2 and STAT-3, Bcl-2 are
common property of apoptosis resistant cancer cells. For example, Bcl-2
is an important target for sensitization lymphoma and breast cancers
[25]. Overexpression of Bcl-2 is a prognostic factor for survival of pa-
tients with gastric cancer [26]. It is suggested that increased expression
of anti-apoptosis genes such as COX-2 and NF-kB has a direct relation
with tumor growth and invasion in various cancer cells such as breast,
prostate, colorectal, bladder, pancreatic, glioma, lung, and melanoma
cancers [27–34].
Melatonin, a natural circadian hormone, has shown interesting
properties for modulation of both normal tissues and tumor responses
to radio- and chemotherapy [35–38]. It is a potent antioxidant and
immune modulatory agent with an ability to prevent cell death in
oxidative stress conditions [39,40]. Furthermore, melatonin can inter-
rupt redox activity, inﬂammation, and cell death mechanisms that may
lead to sensitization of cancer cells to radiation and chemotherapy
[41–44]. In this review, we aimed to describe various eﬀects of mela-
tonin on apoptosis signaling pathways for both normal tissues and
cancers.
2. Mechanisms of apoptosis induction by radiation/chemotherapy
Apoptosis is a physiological cell death mechanism that is necessary
for growth and development of human and other organisms. Apoptosis
can prevent the growth and division of cells with genomic instability
and also pre-cancerous cells [45–47]. During stress conditions such as
oxidative stress and massive DNA damage, apoptosis can occur espe-
cially for cells with high proliferation rate, and high expression of pro-
apoptotic genes [48,49]. Apoptosis is a complicated process mediated
by a group of enzymes known as caspases. Caspases are involved in
both initiation and progression of apoptosis. Caspases 8–10 are initiator
apoptosis caspases, while caspases 2–7 and caspases 11–13 are eﬀector
caspases.
Apoptosis can occur through two diﬀerent pathways, including in-
trinsic or extrinsic pathway. The intrinsic pathway of apoptosis med-
iates via mitochondrial pathway, which is associated with the release of
cytochrome c and development of apoptosome complex following en-
gagement with caspase 9. The mitochondrial pathway of apoptosis can
occur following exposure to intracellular or extracellular stimuli.
However, extrinsic pathway of apoptosis is independent of mitochon-
dria and is seen following extracellular stimuli [50–52].
Apoptosis is the most common type of cell death mechanism fol-
lowing exposure of radio/chemosensitive cells to radio- or che-
motherapy [53,54]. Radiation and most of the chemotherapy drugs are
able to attack DNA directly or via radiolysis of water molecules and
generation of free radicals. When cells could not able to completely
repair damaged DNA, they may die through mitotic catastrophe,
apoptosis, autophagy or senescence. However, in some conditions such
as heavy membrane damages after exposure to a high dose of radiation,
necrosis is a probable mechanism of cell death. Evidences have shown
that apoptosis can also occur during mitotic catastrophe or necrosis, a
process known as necroptosis [55–57].
The rate of apoptosis depends on cell type as well as radiation/drug
dose [58,59]. Cells with high proliferation rate and high expressions of
pro-apoptosis genes such as Bax, PUMA, and p53 are sensitive to
apoptosis during stress conditions. Hematopoietic bone marrow, je-
junum and parotid gland cells have high proliferation rate and high
expressions of pro-apoptosis genes including p53 and Bax, compared
with other organs [60,61]. Interestingly, lymphocytes B and T, which
do not have mitotic activity are very sensitive to apoptosis. It is prob-
able that high expressions of p53 and Bax in addition to low expressions
of anti-apoptotic genes such as Bcl-2 play a key role in apoptosis in-
duction of lymphocytes after exposure to radiation and chemotherapy
[62]. In addition to p53 dependent pathways, cells may undergo
apoptosis independent of p53, via stimulation of cell death receptors on
the cell membrane surface. These receptors which can trigger TGF-β
and TNF-α include TGFBR1, TGFBR2, TNFR, Fas ligand (FasL) and TNF-
related apoptosis-inducing ligand (TRAIL). Among these receptors, FasL
and TRAIL are more common for inducing apoptosis. TNFR, TRAIL and
FasL bind to Fas-associated death domain (FADD), which is able to
activate caspase-8 directly [63–66].
Ceramide is another important mediator of apoptosis. It can be
generated following interaction of free radicals with plasma membrane
phospholipid sphingomyelin, leading to activation of sphingomyelinase
enzyme, which mediates generation of ceramide [67]. It seems that
increased ROS production play a key role in ceramide generation
[68,69]. Ceramide, via mitochondrial depolarization, facilitates the
release of cytochrome c [70]. It also downregulates the expression of
anti-apoptotic genes such as PI3K, leading to increased Bax to Bcl-2
ratio [70,71]. It has been revealed that exposure to ionizing radiation
stimulates generation of ceramide, which facilitates apoptosis by in-
creasing pro-apoptotic gene expression [72]. Ionizing radiation causes
damage to cell membrane and activates acid sphingomyelinase, leading
to ceramide generation through hydrolysis of sphingomyelin. Further-
more, radiation can activate mitochondrial ceramide synthase fol-
lowing damage to DNA [73]. Radiation can also stimulate generation of
ceramide through activation of inﬂammation and reduction/oxidation
(redox) reaction such as upregulation of mitogen-activated protein ki-
nases (MAPKs) and TNF-α–PKC pathway [74,75]. Similar results are
observed for chemotherapy drugs [76]. Furthermore, enhancing cer-
amide production is proposed for overcoming tumor resistance to
chemotherapy, resulting in improving cancer therapy outcome
[77–80]. (Fig. 1).
3. Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a main product of the
pineal gland, which regulates circadian rhythm and several other cel-
lular functions such as modulation of redox state, immune system re-
sponse, etc. [81,82]. In the pineal gland, it is generated following me-
thylation and acetylation of serotonin. However, other organs and cells,
such as bone marrow, lymphocytes, lens, skin, brain, and retina are able
to generate melatonin [83]. The concentration of not circadian mela-
tonin in essentially all biological ﬂuids and local concentration in
peripheral tissues exceed those in the pineal gland and the blood [84].
Melatonin can also be produced by some plants such as rice, olive,
tomato, chamomile, green tea, coﬀee, and cereals [85,86]. Melatonin
regulates cell death in both normal and malignant cells. Interestingly,
melatonin protects most normal cells against toxic eﬀects of ionizing
radiation and chemotherapy, while it may sensitize some cancer cells.
Some studies have suggested that the main eﬀects of melatonin in cells
are mediated through melatonin receptors, including MT1 and MT2. It
has been described beneﬁcial actions of endogenous melatonin thor-
ough its MT1 and MT2 receptors in the modulation of circadian rhythm
disorders, neuroendocrine processes, as well as endogenous melatonin
also has an eﬀect on cancer [87]. Moreover, exogenous melatonin has
therapeutic eﬀects by the trigger of several mechanisms such as anti-
cancer activities following the upregulation of these receptors [87].
Although, there are some evidences that anti-cancer eﬀects of mela-
tonin may be independent from these receptors [88], it is suggested that
expression of MT1 and MT2 in cancer cells increase anti-tumor activity
of melatonin [89]. Upregulation of MT1 in some cancer cells such as
prostate and breast cancers lead to the inhibition of some protein ki-
nases and the phosphorylation of mitogen-activated protein kinases
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(MAPKs), which ultimately mediate the repression of cancer cells pro-
liferation [87].
4. Melatonin and apoptosis in normal tissues following
radiotherapy/chemotherapy
As aforementioned, uncontrolled cell death following exposure to a
high dose of ionizing radiation can interrupt organ functions. Similar
eﬀect may be observed when an organ is exposed to fractionated
radiotherapy for some weeks. Massive death of lymphocytes and pla-
telets may cause some problems such as lymphopenia during the course
of radio- and chemotherapy for patients. Similar problems may be ob-
served as xerostomia and mucositis for head and neck, as well as ab-
dominopelvic cancers. Protection against cell death in these organs is
an interesting aim for ameliorating normal tissue toxicity. Melatonin
has various eﬀects on normal cells that help to alleviate cell death
following exposure to toxic agents such as chemotherapy or radio-
therapy.
4.1. Melatonin enhances antioxidant defense against radiation/
chemotherapy
At the ﬁrst level, melatonin is considered as a radioprotector and
chemoprotector due to its direct action as a free radical scavenger, al-
leviating DNA damage and cell death. Melatonin is able to neutralize
the free radicals produced by radiation more potently compared to
other antioxidants such as glutathione [90]. In addition, several studies
have conﬁrmed that cellular antioxidant defense is also promoted by
melatonin following exposure to radiation [91–95]. Gil et al. described
the protective eﬀect of melatonin on rat's intestinal damage. They ir-
radiated rats with 7.5 Gy X-rays for 5 consecutive days, followed by
treatment with 45mg/kg melatonin gel for 21 days. Results showed
that melatonin prevented damage to the intestine via stimulation of
antioxidant defense and amelioration of oxidative stress and in-
ﬂammation. Moreover, melatonin also provided mitochondrial protec-
tion, which in turn resulted in a signiﬁcant reduction of Bax/Bcl2 ratio
in comparison to irradiated rats [96]. The direct and indirect anti-
oxidant properties of melatonin may play a key role in amelioration of
DNA damage and genotoxicity, as well as apoptosis following exposure
to radiation. Anti-oxidant and anti-apoptotic eﬀect of melatonin against
ionizing radiation has been also attested in human skin ﬁbroblasts by
Kim et al. They treated cultured human skin ﬁbroblasts with 10−5 M
melatonin before exposing cells to 8 Gy radiation. Results showed that
melatonin reduced apoptosis in ﬁbroblasts without reduction in p53,
while it reduced oxidative injury remarkably [97]. Similar results were
obtained in mouse cerebellum. Melatonin attenuated oxidative DNA
damage and apoptosis induction following irradiation of mouse cere-
bellum with Fe2+ ions [98]. Anti-oxidant and protective eﬀects of
melatonin against oxidative stress induced by chemotherapy drugs such
as cisplatin, cyclophosphamide, doxorubicin, methotrexate, and adria-
mycin have shown for normal tissues in animal models [99–104].
4.2. Melatonin modulates genes that are involved in DNA repair and cell
death
In addition to antioxidant properties, melatonin is able to boost the
activities of DNA repair enzymes and modulate the expression of genes
that are involved in cell death. The activation of p53 plays a key role in
promoting the repair of both endogenous and chemotherapy-induced
DNA damage, as well as, in preventing apoptosis [105,106]. It has been
described that melatonin directly phosphorylates p53, leading to the
activation of DNA repair [106]. Indeed, the blockage of melatonin re-
ceptors and the resulted abrogation of melatonin action impairs the
p53-dependent DNA repair response, which may lead to cell death
[105]. Moreover, a recent publication has shown that melatonin is able
to potentiate diﬀerent pathways of DNA repair including base excision
repair (BER), mismatch repair (MMR), nucleotide excision repair
(NER), homologous recombination (HR), and nonhomologous end-
joining (NHEJ) [107]. In response to cyclophosphamide induced DNA
damage in rats bone marrow cells, melatonin can enhance the expres-
sion of NER pathway genes, including Xpf [108]. For the ﬁrst time,
Vijayalaxmi et al. showed that pre-treatment of human peripheral
lymphocytes with melatonin boost DNA repair and attenuates gamma
ray-induced DNA damage [109,110]. In response to radiation, mela-
tonin has shown that is able to trigger DNA repair responses via upre-
gulation of genes that are involved in single and double strand break,
and also upregulation of BER pathway genes [111].
4.3. Melatonin may aﬀect expression of pro-apoptosis genes
As mentioned, melatonin is a potent antioxidant and stimulator of
DDR, which alleviate DNA damage and apoptosis after chemo-
Fig. 1. Mechanisms of apoptosis in-
duction following radiation/che-
motherapy. Radiation and ROS trigger
upregulation of growth factors and
apoptosis receptors, which stimulate
the regulation of pro-apoptosis caspase
proteins. Caspases 8 and 9 stimulate
Bax penetration into mitochondria and
development of apoptosome complex
following release of cytochrome c (Cyto
C). This complex and some other cas-
pase proteins such as caspase 3, 6 and 7
are responsible for appearance apop-
tosis morphology like membrane
shrinkage and degradation of DNA.
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radiotherapy. Furthermore, due to the regulatory action of melatonin
on apoptosis genes, this neurohormone seems to play a key role in
preventing cell death.
Khan et al. evaluated the anti-apoptotic eﬀect of melatonin on mice
organs including bone marrow, spleen, and gastrointestinal system.
Mice were treated with 100mg/kg melatonin and then exposed to an
acute dose of 7.5 Gy cobalt-60 gamma rays. These results showed that
melatonin enhanced the expression of Bcl-2 and reduced Bax/Bcl-2
ratio. This was associated with a reduction of apoptosis, preservation of
villi and crypts in intestine, as well as increased number of bone
marrow cells [112]. Similar ﬁndings have observed for spermatogenesis
in mice. As previously mentioned, testis is one of the most sensitive
organs to ionizing radiation and chemotherapy drugs. Spermatogonia
and spermatids are very sensitive to apoptosis following exposure to
even low doses of ionizing radiation. Khan et al. has revealed the
protective eﬀect of melatonin against apoptosis induction in mice testis
after exposure to radiation. Mice were treated with 100mg/kg mela-
tonin before exposure to 5 Gy gamma rays. Melatonin was able to at-
tenuate oxidative injury and DNA damage caused by gamma rays in
spermatogonia and spermatid cells. Moreover, melatonin also reduced
Bax/Bcl-2 ratio, caspase-3, caspase-9, cytochrome c, p21 and p53, in-
dicating its potent anti-apoptosis eﬀect on the testis [113].
In addition to radiation, melatonin alleviates toxicities due to che-
motherapy in normal tissues. Melatonin can reduce renal toxicity in-
duced by cisplatin in rats via upregulation of Bcl-2 and reduction of cell
death [104,114–116]. Barberino et al. evaluated the protective eﬀect of
melatonin against cisplatin-induced toxicity in mouse ovaries. Mice
were treated with 5, 10 or 20mg/kg melatonin for 3 days before in-
jection of 5mg/kg cisplatin. Results showed that melatonin reduced
apoptosis, which was associated with decreased mitochondrial injury,
ROS production, and stimulation of GSH level. Melatonin also reduced
caspase-3 and Bcl-2, and improved follicles' morphology. Further ana-
lyses showed that the protective eﬀect of melatonin in ovary cells was
mediated through MT1 receptor [117]. Cisplatin can stimulate super-
oxide production via upregulation of NADPH oxidase enzymes, which
cause DNA damage in cochlear cells. This is associated with accumu-
lation of cells in G2 phase of cell cycle, inhibition of proliferation, and
induction of apoptosis [118]. Melatonin has been proposed for alle-
viating ototoxicity induced by cisplatin [119].
Overall, these studies indicate that melatonin would be a potential
radioprotector and chemoprotector, due to its capacity to regulate the
highly collateral toxicity of radio- and chemotherapies in normal tis-
sues. The key ﬁnding is that melatonin ameliorates the radiation-in-
duced apoptosis and cell damage in healthy tissues by the regulation of
diﬀerent molecular mechanisms. This neurohormone not only is able to
neutralize free radicals via direct interactions, but also stimulates cel-
lular antioxidant defense systems. In addition, melatonin also enhances
DNA repair capacity by the regulation of DDR genes. Finally, melatonin
also ameliorates apoptosis responses by the upregulation of anti-apop-
tosis Bcl-2, as well as the downregulation of pro-apoptosis Bax and
caspase genes (Fig. 2).
5. Melatonin and apoptosis in cancer
Apoptosis is one of the most important mechanisms of tumor cell
death following radio- and chemotherapy, and plays a key role in tumor
control [19,120,121]. For radiation doses lower than 1 Gy, as observed
in hyper-fractionated radiotherapy, apoptosis is the main mechanism of
cell death in most tumors. However, in higher doses such as those used
in conventional or hypo-fractionated radiotherapy, apoptosis is one of
the most important cell death mechanisms [122,123]. Both radiation
and most of the chemotherapy drugs can stimulate apoptosis through
production of ROS and DNA damage. Apoptosis is stimulated by
membrane injury, mitochondrial malfunction and disruption of redox
responses. In contrast to normal tissues, melatonin has shown to be able
to potentiate apoptosis in most cancer cells. Studies have revealed that
melatonin increases endogenous production of ROS and facilitates
apoptosis via DNA damage, and changes in the mitochondria [124].
Furthermore, melatonin can upregulate apoptosis receptors in the
tumor cells' surface [125]. In contrast to normal cells, results of ex-
perimental studies have shown that melatonin may attenuate anti-
oxidant defense as well as survival mechanisms of most cancer cells.
However, it doesn't occur in all cancer cells. For example, in LNCaP
prostate cancer cells, melatonin can protect against ionizing radiation
due to increasing level of glutathione. Therefore, for sensitization of
LNCaP cancer cells to apoptosis, melatonin should be combined with an
inhibitor of glutathione [126]. In this section, the mechanisms of
apoptosis stimulation by melatonin and its possible radio/chemosensi-
tization eﬀect on tumor cells are described.
5.1. FasL pathway in cancer regression: role of melatonin
FasL is one of the most important targets for induction of apoptosis
and sensitization of cancer cells to radiation/chemotherapy. Evidences
have shown that this ligand is an important pathway for killing cancer
cells by cytotoxic T lymphocytes (CD8+ T-cells) and natural killer cells
(NKCs) [127]. However, there are some challenging results because the
expression of FasL in tumor endothelium can lead to killing of CD8+ T-
cells and tumor escaping death by immune system [128]. Increase of
circulating FasL during tumor growth may lead to reduction of Fas-
mediated apoptosis and immune escaping tumor cells [129]. An ex-
perimental study showed that FasL in tumors with low expression of
FasL facilitates tumor growth, while tumors with high expression of
FasL are sensitive to apoptosis by CD8+ T-cells [130]. This pathway of
apoptosis plays a key role in the toxic eﬀect of ionizing radiation and
some chemotherapy drugs such as doxorubicin, ﬂudarabine, cisplatin
and metalloproteinase inhibitors [131–134].
In addition to melatonin's role in stimulating apoptosis in cancer
cells, it can protect lymphocytes against apoptosis via FasL pathway.
This helps to activate the immune system against cancer [135]. Mela-
tonin can induce extrinsic pathway of apoptosis in Ewing's sarcoma
cells, which potentiates anti-cancer eﬀect of chemotherapy drugs such
as vincristine and ifosfamide. Interestingly, this eﬀect is associated with
ROS production, which may be involved in the activation of caspase-8
and apoptosis [136]. Treatment of Ewing's sarcoma cells with mela-
tonin also showed an increase in the expression of both Fas and FasL,
which mediate activation of caspase-8 in these cells [137]. It has been
attested that melatonin induces apoptosis through upregulation of dif-
ferent death receptors in human malignant haematological cell lines. In
vitro evaluation showed that among the diﬀerent pathways, Fas/FasL
plays central role in apoptosis induction in malignant haematological
cells. Treatment of these cells with melatonin leads to activation of
redox reactions within cells following upregulation of Akt, which
caused increased production of ROS and activation of Fas/FasL
pathway [138].
5.2. P53 in apoptosis and tumor resistance; role of melatonin
Among the diﬀerent tumor suppressor genes, mutation in p53 is the
most common and found in a wide range of tumors. On the other hand,
several studies have shown that attenuation of p53 is involved in
apoptosis escape by pre-malignant and malignant cells, leading to in-
itiation and progression of tumorigenesis [139,140]. The expression of
p53 may predict chemo/radiation sensitivities of cancer cells
[141–145]. Furthermore, stimulation of p53 activity is known as an
interesting strategy for improving response of tumors to radiation and
chemotherapy via increasing apoptosis induction [146–148]. The ex-
pression of p53 is observed at the basal level, but its activation occurs at
post-translational modiﬁcation following degradation of MDM2 and
preventing ubiquitination of p53 [149,150]. Phosphorylation and de-
gradation of MDM2 can be triggered by some protein kinases, such as
ataxia-telangiectasia mutated (ATM) kinase, JNK, p38, etc. [151]. P53
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has a key role in the progression of both extrinsic and intrinsic pathway
of apoptosis. It is involved in the stimulation of FasL regulation and also
activation of caspase-8, which mediate Bid activation [152]. Bid is
transferred to the mitochondrial membrane, leading to activation of
Bax and release of cytochrome c [153,154]. On the other hand, Bcl-2,
an AKT downstream anti-apoptotic protein under the control of p53,
can be inhibited following p53 activation [155]. p53 also stimulates the
upregulation of caspases and progression of extrinsic apoptosis via
suppression of IAPs [156].
Treatment of MCF-7 breast cancer cells with melatonin can increase
the activity of p53 remarkably, leading to sensitization of cells to ra-
diation. Alonso-González et al. showed that while exposure to radiation
stimulates p53 activity, treatment with melatonin can further improve
it. Thus, it may be involved in the radiosensitive eﬀect of melatonin
[157]. Similar results were observed when MCF-7 cells were treated
with arsenic trioxide and melatonin. Arsenic trioxide, when adminis-
tered alone, can activate p53 and p21, and increases the expression of
Bax, leading to induction of apoptosis, reduction of viability, and ac-
cumulation of cells in G1 phase of cell cycle. Treatment with the
combination of melatonin and arsenic trioxide could amplify apoptosis
and p53 activity [158]. The beneﬁcial role of melatonin on p53 activity
was observed by this group when MCF-7 cells were treated with doc-
etaxel chemotherapy drug. Arsenic trioxide caused a signiﬁcant re-
duction in p53 gene expression. Treatment with melatonin could am-
plify p53 activity and late apoptosis [159].
5.3. Melatonin and mitochondria
Mitochondria metabolism plays a key role in the regulation of
apoptosis in mammalian cells. In addition to the intrinsic pathway of
apoptosis that mediates development of apoptosome complex following
cytochrome c release, mitochondria have a central role in regulation of
redox state in relation with other organelles such as endothelial re-
ticulum, and also inﬂammatory cells [160–162]. Given that cancer cells
are characterized by a highly glycolytic bioenergetic proﬁle (Warburg
eﬀect) [163], the modulation of mitochondrial respiration and the re-
sulted mitochondrial-based apoptosis are of paramount importance in
cancer cell biology. For this reason, several researches groups are fo-
cusing on the study of potential drugs that can regulate cancer bioe-
nergetics. This strategy is also gaining more relevance under conditions
of hypoxia, in which mitochondrial metabolism is downregulated, re-
sulting in a cancer resistance factor to apoptosis. However, it has been
recently demonstrated that only the energy metabolism of some types
of cancer cells is modulated by the administration of melatonin. Those
cancer cells which rely also in mitochondrial metabolism for ATP
production, such as embryonal carcinoma cells, a melatonin-induced
mitochondrial respiration modulation and antiproliferative actions are
observed [164]. Conversely, those cancer cells which are associated
with a highly glycolytic proﬁle seem to be resistance to display a mi-
tochondrial bioenergetic modulation by the action of melatonin. In-
deed, MCF-7 breast tumor cells exhibited a disruption of mitochondrial
respiration after its treatment with melatonin [165]. Curiously, it has
been demonstrated in pituitary prolactin-secreting tumor that mela-
tonin disrupts the activities of the four mitochondrial complexes,
leading to a mitochondrial dysfunction and the induction of apoptosis
[166]. Further investigation the action of melatonin on mitochondrial
function, it has been found that melatonin stimulates the citotoxicty of
head and neck cell carcinoma by the induction of altered mitochondrial
function, that ultimately leads to mitochondrial ROS production and
the resulted upregulation of apoptosis and mitophagy processes [167].
For example, treatment of hepatocellular carcinoma cells with cisplatin
leads to ROS production and reduction of cell viability, while its com-
bination with melatonin can amplify endogenous production of ROS
[168]. Moreover, melatonin has been shown to increase mitochondrial
Fig. 2. Mechanisms of preventing DNA damage and apoptosis by melatonin in normal tissues. Melatonin is able to prevent radiation toxicity in diﬀerent levels. At the
ﬁrst level, melatonin neutralizes produced free radicals by radiation or chemotherapy. Then, it can attenuate various signaling cascades that are involved in
inﬂammation and production of endogenous free radicals. Inhibiting NF-kB expression and translocation, and suppression of mitochondria, iNOS and COX-2 by
melatonin cause reducing endogenous ROS/NO, which lead to boosting DNA repair and increasing normal tissues tolerability.
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generation of ROS, leading to endothelial reticulum stress and apoptosis
in colorectal cancer cells [169]. Similar results were observed for neural
cancer cells following treatment with melatonin [170]. Uguz et al.
showed that mitochondria play a central role in ROS production and
apoptosis of rat pancreatic tumor cells when treated with a combination
of melatonin with chemotherapy drugs including 5-FU, cisplatin, or
doxorubicin. After exposure to these chemotherapy drugs, cells showed
mitochondrial membrane depolarization and an augmentation of ROS
production. When cells were treated with melatonin combination with
these drugs, oxidative injury and reduction of cellular viability was
ampliﬁed for all drugs [171]. Therefore, these beneﬁcial properties of
melatonin on mitochondrial function should be further studied for
widespread clinical applications, being able to be a possible adjuvant of
radio- and chemotherapies of some type of cancers.
5.4. Melatonin and mitophagy
Mitophagy is a type of autophagy that degrades and digests injured
mitochondria [172]. In response to some conditions like hypoxia in
tumor, mitophagy reduces mitochondria mass, which lead to reducing
oxygen generation and nutrition consumption. This is associated with
preserving fuel in cells and increasing survival [172,173]. However,
increased mitophagy response following treatment of cancer cells with
anti-cancer drugs may indicate increased rate of mitochondrial dys-
function [174]. A study showed that treatment of head and neck cancer
cell lines including Cal-27 and SCC-9 with rapamycin cause reducing
oxygen consumption and metabolism. In combination with melatonin,
rapamycin further induces mitochondrial dysfunction. Analyses showed
that increased apoptosis and mitophagy is resulting from damaged
mitochondria following treatment with rapamycin and melatonin
combination [174]. Similar results were observed when hepatocellular
carcinoma (HCC) was treated with a combination of melatonin and
sorafenib [175]. By contrast, melatonin has shown that augments TNF-
mediated apoptosis in HeLa cancer cells via suppression of mitophagy.
Although treatment with TNF-α induced apoptosis, it activated mito-
phagy. When cells treated with combination of melatonin and TNF-α,
mitophagy response was inhibited [176]. It is mainly due to the fact
that an excessive mitophagy activation leads to the blockade of apop-
tosis and the development of cancer therapeutic resistance [177].
Therefore, melatonin treatment is able to enhance apoptosis via sup-
pressing mitophagy (172). Melatonin-induced inhibition of mitophagy
in other cancer cells such as Hela cells also has shown that increase
apoptosis and sensitize these cells to anti-cancer drugs [178].
6. Melatonin suppresses anti-apoptosis mediators in cancer
In addition to stimulation of pro-apoptotic genes' expressions and
disruption of redox state in cancer cells, melatonin is able to attenuate
the activity and upregulation of anti-apoptotic mediators. NF-κB, COX-
2, PI3K, AKT, and hypoxia are the most common anti-apoptotic factors,
which mediating resistance to radio- and chemotherapy in a wide range
of cancers. In this section, we explain the mechanisms of apoptosis
resistance in tumors against chemotherapy and radiation, and also re-
view the beneﬁcial roles of melatonin in overcoming apoptosis re-
sistance via these signaling pathways.
6.1. NF-κB in tumor resistance to apoptosis: role of melatonin
NF-κB is one of the most important and the most studied target in
cancer cells, for induction of cell death and overcoming tumor re-
sistance. Studies have shown that the expression of NF-κB is higher in
most cancer cells compared to normal cells. Exposure of cancer cells to
ionizing radiation or chemotherapy drugs stimulates more upregulation
of NF-κB, which leads to adaptation to subsequent doses of radiation/
chemotherapy. The main reason for its chronic upregulation is the da-
mage to DNA and cell death especially via necrosis or necroptosis,
which is observed following apoptosis. After cell disruption, cellular
contents such as oxidized DNA and high mobility group box 1 (HMGB1)
protein are able to stimulate upregulation of some toll like receptors
(TLRs) such as TLR2, 4, 5 and 9. These TLRs induce regulation of
MyD88 and TRIF, which are able to phosphorylate and degrade IkB,
leading to nucleus translocation of NF-κB.
NF-κB regulates generation of several inﬂammatory cytokines such
as IL-1, IL-6, IL-8, IL-18, TNFα, and IFNγ. These cytokines further sti-
mulate the expression of NF-κB in a positive feedback loop. NF-κB has
been shown to attenuate apoptosis through TNFR and FasL [179].
Furthermore, c-Rel subunit of NF-κB is able to suppress TRAIL pathway,
leading to resistance to apoptosis in cancer cells [180]. NF-κB has an
anti-apoptosis role due to its ability to activate inhibitors of apoptosis
(IAPs). These molecules which include some subfamilies such as cIAP-1,
cIAP-2, XIAP and Survivin, suppress activities of pro-apoptosis caspases
[181]. Targeting these molecules has been proposed for sensitization of
cancer cells to radiation and chemotherapy [182,183].
NF-κB also is involved in intrinsic pathway of apoptosis. The en-
doplasmic reticulum (ER) stress that occur following oxidative stress
conditions can induces phosphorylation and degradation of IkB and NF-
κB nuclear translocation in cancer cells [184]. ER stress responses up-
regulate XIAP expression following stimulation and translocation of NF-
κB [185]. Moreover, it is reported that ER stress may activate NF-κB
following STAT-3 induction, independent from IkB pathway [186]. NF-
κB, via upregulation of Bcl-2, reduces Bax penetration into mitochon-
dria and development of apoptosome complex, which is necessary for
the intrinsic pathway of apoptosis [187].
NF-κB is one of the critical targets of melatonin. At ﬁrst, melatonin
is able to inhibit the upregulation of NF-κB upstream genes including
MyD88 and TRIF, which are regulated by some TLRs such as TLR4
[188,189]. In addition, melatonin is able to directly prevent IkB
phosphorylation and degradation. Melatonin can inhibit translocation
of NF-κB into the nucleus and also prevents chronic inﬂammation by
attenuating the release of inﬂammatory cytokines and chemokines.
These properties of melatonin make it an appropriate candidate for
sensitization of cancers with high expressions of NF-κB to radio- and
chemotherapy via increasing the rate of apoptosis. Treatment of colon
cancer cells including SW480 and LoVo cell lines with melatonin plus
ursolic acid showed potent synergic eﬀect on killing cancer cells. Fur-
thermore, this treatment combination reduced the viability of cells by
1.3-fold for SW480 and 2.6-fold for LoVo cells. Apoptosis rate was also
increased by 2-fold for SW480 and 1.5-fold for LoVo cells. Melatonin
could potentiate the eﬀect of ursolic acid via preventing NF-κB binding
and p300 recruitment, leading to reducing COX-2 gene expression and
increasing cytochrome c release [190]. Similar suppressive eﬀect of
melatonin on colon cancer cells has been reported when combined with
5-FU. It has been shown that the combination of melatonin with 5-FU
reduces phosphorylation of IKKα, IκBα and p65, and also mediates
translocation of p50/p65 from the nucleus to cytoplasm. This resulted
in preventing the binding of NF-κB to iNOS promoter, which inter-
rupted iNOS signaling pathway. Selective targeting of iNOS conﬁrmed
that melatonin reduces the viability of colon cancer cells via inhibition
of this pathway [191].
In addition to chemotherapy, melatonin sensitizes cancer cells to
radiation via NF-κB targeting. Usually, the expression of NF-κB in-
creases in diﬀerent cancer cells following exposure to radiation. For
example, in thyroid cancer cells, an increase in the level of NF-κB in the
nucleus and cytoplasm was observed after exposure to 2 Gy. Treatment
with melatonin reduced the phosphorylation and nuclear expression of
NF-κB/p65. This was associated with increased apoptosis (by more than
2-fold compared to radiation alone) and reduction of tumor invasive
markers [192]. Melatonin has also been shown to sensitize some other
cancer cells to radiation due to NF-κB inhibition and apoptosis induc-
tion [193,194]. The eﬀect of melatonin on the expression of NF-κB may
vary in diﬀerent cancer cells. Thus, it may not cause inhibition of NF-κB
in all cancer cells [195,196].
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6.2. Modulation of MAPKs in tumor by melatonin
Studies have shown that activation of MAPKs has a close relation
with initiation and progression of various types of malignancies. MAPK
signaling is regulated by some subfamilies including Jun N-terminal
kinase (JNK), extracellular-signal-regulated kinase (ERK) and p38,
which regulate several functions such as proliferation and apoptosis
through interaction with other pathways such as PI3K and AKT
[197,198]. Several studies proposed that these molecules have key roles
in apoptosis resistance of some tumors to chemotherapy and radio-
therapy, thus targeting them may promote cell death, leading to im-
proving therapeutic eﬃciency [199–204]. Activated ERK may interrupt
apoptosis induction by TGF-β signaling pathway [205]. It has also been
revealed that targeting ERK can promote apoptosis in glioblastoma cells
via TRAIL pathway [206]. MAPKs may also aﬀect the pro-apoptosis
activity of p53 [207]. The contribution of MAPKs in resistance of other
cancers, such as breast, gastric and esophageal has shown by several
other studies [208–211].
Recently, a large number of studies have focused on the dual role of
melatonin on PI3K/AKT axis and MAPKs cascades in normal cells and
cancer cells. Therefore, the modulation of these pathways has become
of paramount importance for cancer radio- and chemotherapy to
overcome cancer-drug resistance. While melatonin activates the AKT
pathway on healthy cells exerting its neuroprotective property, this
pathway is inhibited in melatonin treated cancer cells [212–214]. It has
been demonstrated that these opposite eﬀects are because of the al-
ternate G-protein coupling of the receptor in healthy cells than trans-
formed cancer cells [215]. In addition, PI3K/AKT/mTOR pathway that
triggers the Ras/MEK/ERK compensatory pathway is modulated by MT
receptors [216,217]. The regulation of these pathways has a crucial role
in cell fate. Some experimental studies have revealed that melatonin
may stimulate apoptosis and reduce resistance in some cancer cells via
inhibition of MAPKs genes. However, it has been shown that melatonin
may upregulate MAPKs in some cancer cells such as SGC7901 gastric
cancer cells, and it may inhibit cell proliferation through other sig-
naling pathways [218]. It has been proposed that melatonin may in-
crease redox activity (thus stimulating cell death) via inhibition of NF-
κB and activation of MAPKs [219]. Melatonin stimulates activation of
pro-caspase enzymes and sensitizes gastric cancer cells to cisplatin via
activation of p38 and JNK, as well as NF-κB suppression [220]. How-
ever, in human hepatocellular carcinoma, melatonin can enhance JNK
suppression by sorafenib, leading to further upregulation of caspase-3
and induction of apoptosis [221]. Treatment of Eca109 and KYSE150
cells as in vitro and xerograph models with melatonin (5mM) have
shown to inhibit pMEK and pErk. Exposure of these cells to 5-FU did not
cause any reduction in the phosphorylation and expression of pMEK
and pErk, while its combination with melatonin showed synergistic
eﬀect. Results indicated that inhibition of MEK/ERK pathway by mel-
atonin increases apoptosis and reduces survival of cancer cells. Flow
cytometry results showed that colony formation was reduced by 40%
for Eca109 and nearly 70% for KYSE150 cells, when cells were treated
with the combination of 5-FU and melatonin compared to 5-FU alone
[222].
6.3. Melatonin and COX-2
Cyclooxygenase-2 (COX-2), which regulates secretion of pros-
taglandins following metabolism of arachidonic acid, is known as a
potent inﬂammatory mediator, which is involved in the initiation and
progression of a wide range of malignancies. Evidences from experi-
mental and clinical studies have revealed that increased expression of
COX-2 is associated with tumor resistance to radiation/chemotherapy
and poor survival rate [223–228]. On the other hand, targeting COX-2
using selective or non-selective inhibitors can sensitize tumor cells to
both radiation and chemotherapy drugs [229]. It has been revealed that
inhibition of COX-2 induces apoptosis, which is associated with
upregulation of death receptors such as TRAIL and FasL [230]. Ex-
posure to ionizing radiation and chemotherapy drugs cause DNA da-
mage and necrosis, which stimulate more upregulation of COX-2 and
generation of prostaglandins. Therefore, it has been proposed the use of
COX-2 inhibitors for promotion of apoptosis, and thereby sensitizing
cancer cells to radiation/chemotherapy [231].
The combination of melatonin with chemotherapy drugs has been
shown to attenuate COX-2 upregulation, thus amplifying apoptosis in
some cancer cells [232–234]. The suppressive eﬀect of melatonin on
COX-2 plays a key role in the promotion of apoptosis in hepatocellular
carcinoma, including HepG2 and SMMC-7721 cells. Through this me-
chanism, melatonin inhibits PI3K/AKT pathway, leading to down-
regulation of IAP genes, including cIAP-1&2, XIAP and survivin. Se-
lective targeting of COX-2 and PI3K using their respective inhibitors
(NS398 and LY294002) produced similar eﬀects, which conﬁrmed that
suppression of COX-2 pathway by melatonin leads to sensitization of
HepG2 and SMMC-7721 cells to apoptosis [235].
6.4. Melatonin and PI3K pathway
PI3K plays a key role in apoptosis resistance in a wide range of
cancer cells. Some studies have shown that PI3K, via activation of NF-
kB, induces upregulation of Bcl-2, leading to prolonged survival of
cancer cells [236–239]. Upregulation of PI3K also triggers activation of
some apoptosis inhibitors such as survivin, which mediate resistance to
anti-cancer drugs [240]. PI3K activation can also stimulate HIF-1
during hypoxia, thus suppresses apoptosis and promotes tumor growth
[241]. Targeting PI3K has been shown to attenuate DNA damage re-
sponses, induces apoptosis, and sensitizes cancer cells to chemotherapy
and ionizing radiation [242–247].
Melatonin facilitates apoptosis and reduction of viability in some
cancer cells through targeting PI3K pathway. Inhibition of PI3K by
melatonin can reduce the expression of IAP proteins, such as cIAP-1,
cIAP-2, survivin, and XIAP [248]. Treatment of SW480 and LoVo cells
with a combination of melatonin and 5-FU showed that melatonin
could inhibit phosphorylation of AKT. Further evaluations showed that
selective inhibition of PI3K by PI3K-speciﬁc inhibitor LY294002 am-
pliﬁes inhibition of cell viability, which conﬁrmed a pivotal role of this
pathway in the inhibition of tumor cells' proliferation. An in vivo xer-
ograph study also conﬁrmed that downregulation of PI3K/AKT
pathway in the mentioned cancer cells is associated with increased level
of pro-apoptotic caspases and also PARP [191].
6.5. AKT pathway and role of melatonin
In addition to PI3K, AKT can be stimulated and upregulated by some
other signaling pathways such as PTEN and Forkhead Box Class O
(FOXO). After p53, PTEN is the second most frequently mutated tumor
suppressor gene in cancers. Mutations in this gene has been reported
with mutagenesis and uncontrolled proliferation, which lead to tumor
growth. It seems that AKT upregulation has a direct relation with mu-
tation in PTEN and plays a key role in the proliferation of tumors with
mutated PTEN [249]. Glycogen synthase kinase-3 (GSK-3) is another
upstream AKT gene which has also been proposed as a target for cancer
suppression [250]. A 50-fold increase in AKT expression in human
pancreatic cells has been reported [251]. AKT upregulation has been
revealed for some other cancers such as breast, ovarian, adenomas,
colon, and colorectal [252–254].
Treatment of oesophageal squamous cell carcinoma with melatonin
showed that it inhibits AKT through GSK3β inhibition. This led to a
signiﬁcant increase in pro-apoptotic caspases as well as a reduction in
viability. Selective inhibition of GSK3β showed similar results, which
conﬁrmed the role of this pathway in cancer cells' resistance. Exposure
of oesophageal squamous cell carcinoma to 5-FU led to a remarkable
increase in pAKT and AKT. However, when cells were treated with a
combination of 5-FU and melatonin, the protein levels of both pAKT
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and AKT reduced dramatically [191]. Melatonin can potentiate apop-
tosis induction and anti-tumor activity of sorafenib via inhibition of
AKT pathway. It has been demonstrated that treatment of hepato-
carcinoma cell lines with a combination of sorafenib and melatonin
inhibits cells' proliferation, which is associated with AKT down-
regulation. AKT stimulation can reverse the inhibitory eﬀect of this
combination [255]. This is associated with mitochondrial membrane
depolarization and ROS production, as well as upregulation of pro-
apoptotic genes including PARP and Bax [175].
6.6. Hypoxia-induced apoptosis resistance: modulatory role of melatonin
It has been conﬁrmed that hypoxia in tumor cells plays a key role in
resistance of the cancer cells to radio- and chemotherapy. Hypoxia
leads to upregulation of hypoxia-inducible factor 1 (HIF-1), which
regulates a plethora of target genes changing the physiological condi-
tions of TME for promotion of angiogenesis and multidrug resistance
[256,257]. One of the reasons for resistance of hypoxic cells within a
tumor to chemo/radiation therapy is downregulation of TRAIL pathway
of apoptosis. It has been reported that hypoxia, via increasing the
phosphorylation of STAT3, promotes resistance to chemotherapy drugs
[258]. Targeting STAT3 in combination with radiation/chemotherapy
is associated with overcoming tumor resistance and inducing pro-
apoptotic genes, as well as inhibition of anti- apoptotic Bcl-2 family
genes [259–263]. Evidences have also shown that TRAIL pathway is a
main pathway of apoptosis, whose its regulation is inhibited during
hypoxia, leading to increasing the expression of HIF-1 [264,265].
Some evidences have revealed that melatonin inhibits HIF-1 upre-
gulation and apoptosis resistance in hypoxia condition [266–269]. Park
et al. showed that treatment of human colon cancer cells with mela-
tonin reduces hypoxia-induced TRAIL apoptosis resistance. Their re-
sults indicated that the inhibition of PI3K and NF-kB by melatonin is
probably involved in the increased expression of TRAIL and apoptosis
incidence. Results showed that treatment of cells with 100mM mela-
tonin can completely overcome hypoxia-induced TRAIL apoptosis re-
sistance [270]. Melatonin has also shown the ability to attenuate hy-
poxia-induced TRAIL apoptosis resistance through inhibition of HIF-1.
This is also associated with increased activity of p53, Bax penetration
into mitochondria and modulation of mitochondrial transmembrane
potential which facilitates mitochondrial apoptosis [271]. However,
regulation of GIF-1 by melatonin may be diﬀerent in various cancers.
For example, in Ewing's sarcoma cells, melatonin inhibits HIF-1 in an
independent PI3K pathway [272]. (Fig. 3, Table 1).
6.7. Role of melatonin receptors (MT1 and MT2)
Although some studies have shown that anti-cancer eﬀects of mel-
atonin mediate independent from its receptors, there are evidences that
indicates role of melatonin receptors, including MT1 and MT2. These
receptors increase intracellular concentration of GTP that are involved
in the triggering EFGR and modulation of MAPKs. Activation of MT1 by
melatonin also cause depletion of cAMP, and reduces expression of
AKT, leading to the suppression of cancer cells proliferation [273]. In
breast cancer cells, melatonin inhibits estrogen receptor (ER) through
MT1, which cause inhibition of proliferation [274]. Inhibition of ER by
melatonin also has shown that is associated with suppression of DNA
repair and induction of apoptosis, which further amplify eﬀect of ra-
diation [275]. Neutralization of free radicals also suppresses telomerase
and aromatase, thus further amplify cancer inhibition by melatonin
[274]. In contrast to cancer cells, in some normal cells like ovary cells,
melatonin via inducing MT1 stimulates antioxidant defense, leading to
reducing DNA damage and apoptosis [117]. In conclusion, it seems that
stimulation of most eﬀects of melatonin on both tumor and normal cells
that are trigger via MT1 and MT2 play a key role in protective or
sensitization of cells. However, some eﬀects may mediate independent
from these receptors.
7. Conclusion
Radio- and chemotherapy are the most common non-invasive
cancer treatment modalities which may cause serious toxicities to
normal tissues. In addition, cancer cells in response to both Radio- and
chemotherapy upregulate several signaling pathways for preserving
tumor growth via modulatory genes, which are involved in cell death
and survival. Melatonin has interesting properties for oncology aims
because of its protective eﬀect on a wide range of normal tissues, while
it may promote apoptosis in some cancer cells. In normal cells and
tissues, especially chemo/radiosensitive cells such as lymphocytes and
bone marrow, melatonin can reduce DNA damage, enhance DNA repair
and stimulate antioxidant enzymes, thereby alleviating apoptosis and
increase tissue tolerance. Abnormal changes in TME and cancer cells
are appropriate targets for enhancing apoptosis induction by melatonin.
Cancer cells usually have high expression of anti-apoptotic genes such
as NF-κB and Bcl-2, while they may have low p53 activity. Upregulation
Fig. 3. Mechanisms of apoptosis in-
duction by melatonin in cancer cells. In
the most of cancer cells, the expression
of anti-apoptosis genes such as Bcl-2,
NF-kB, COX-2, STAT-3, AKT and PI3K
is high, while the expression and ac-
tivity of some pro-apoptosis genes such
as p53, PTEN and Bax repressed.
Melatonin via downregulation of NF-
kB, COX-2, STAT-3, and AKT attenuate
regulation of Bcl-2. Also, melatonin
reversed reduced expression of apop-
tosis receptors like FasL and TRAIL,
which cause upregulation of Bax and
release of cytochrome c. stimulating
endogenous production of ROS by
melatonin following stimulation of p38
and JNK potentiates apoptosis induc-
tion in cancer cells.
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and activation of pro-apoptotic mediators such as p53 and Bax by
melatonin are involved in the modulation of apoptosis in cancer cells.
Ionizing radiation can increase the activity of p53 in a wide range of
cancer cells. However, some chemotherapy drugs like docetaxel sup-
presses p53 gene expression. Melatonin has shown the ability to amplify
p53 activity in irradiated cancer cells and also reverses its activity in
cells under exposure to docetaxel.
Synchronous modulation of MAPKs and NF-κB has a key role in the
sensitization of some cancer cells to chemotherapy drugs. Emerging
evidences have shown that melatonin is a potent inhibitor of NF-κB in a
wide range of cancer cells. NF-κB inhibition is associated with an in-
crease in the expression of pro-apoptotic genes such as Bax and PUMA
as well as downregulation of anti-apoptotic genes such as Bcl-2, which
facilitate intrinsic pathway of apoptosis. In addition to the intrinsic
pathway, NF-κB suppression by melatonin can potentiate extrinsic
apoptosis pathway via upregulation of dead receptors such as FasL and
TRAIL. FasL stimulation by melatonin may be an interesting target for
sensitization of malignant haematological cells. Evidences have shown
that upregulation of FasL by melatonin is associated with increased
endogenous production of ROS. It seems that activation of p38 and JNK
amplify ROS production and further increases the expressions of ex-
trinsic apoptosis receptors. Some studies have proposed that mi-
tochondria are important targets of melatonin for increasing ROS pro-
duction in some cancer cells such as hepatocellular carcinoma cells. In
combination with some chemotherapy drugs, melatonin has been
shown to increase mitochondria membrane depolarization and super-
oxide generation. Increased mitophagy incidence following treatment
with melatonin have suggested as a marker for mitochondria dysfunc-
tion and cell death. However, in some cancer cells, melatonin has
shown that increase apoptosis via suppression of mitophagy.
PI3K/AKT pathway is one of the most common signaling pathways
upregulated in a wide range of cancer cells and promotes proliferation
and apoptosis resistance. AKT may also be triggered by other pathways
beside PI3K. Melatonin promotes apoptosis in some cancer cells via
suppression of these genes. Hypoxia in tumors also plays a key role in
tumor growth and cancer cells' resistance to radiation/chemotherapy.
HIF-1, as a central player in hypoxia resistance to radiation/che-
motherapy, has a close relation with attenuation of TRAIL pathway of
apoptosis. It is possible that stimulation of PI3K and NF-κB by HIF-1 is
involved in apoptosis suppression by hypoxia. Melatonin via down-
regulation of HIF-1 in tumors can induce upregulation of TRAIL and
sensitize cancer cells to apoptosis.
The combination of melatonin with radiotherapy, chemotherapy or
targeted therapy drugs such as sorafenib has shown interesting results
for sensitization of cancer cells to apoptosis. However, the mechanisms
of apoptosis induction by melatonin in diﬀerent cancer cells may vary.
Hence, knowledge of the molecular mechanisms of apoptosis resistance
in each cancer type is important for eﬃcient combination of melatonin
with other cancer therapy modalities. Although increasing apoptosis
induction is not enough to overcome tumor resistant, melatonin via
modulation of this pathway may facilitate response of tumor to radio-
chemotherapy. It seems that attention to other mechanisms such as cell
cycle arrest, metastasis and antioxidant defense of cancer cells that are
involved in tumor growth are necessary. Melatonin in some cancer cells
may protect against toxic eﬀects of radiation and chemotherapy that
should be considered.
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